Core Insights - Aflac Incorporated (NYSE:AFL) is recognized as one of the 14 Best Affordable Dividend Stocks to buy according to analysts [1] - Wells Fargo analyst Elyse Greenspan raised the price target for Aflac to $118 from $109 while maintaining an Equal Weight rating, reflecting a shift in valuation approach and updated EPS estimates for 2027 and 2028 [2] Financial Performance - In Q4 2025, Aflac reported net earnings of $2.64 per diluted share and adjusted earnings of $1.57 per diluted share, indicating strong financial performance [3] - Aflac Japan experienced a sales increase of 15.7% in Q4 and 16% for the full year, driven by the success of the Miraito cancer insurance product, which saw a 35.6% sales increase [3] - Aflac U.S. generated nearly $1.6 billion in new sales in 2025, with over one-third of that amount coming in Q4 [4] Strategic Initiatives - The company emphasized a focus on profitable growth, careful underwriting, and disciplined expense management, with a premium persistency rate of 79.2% [4] - Aflac's board approved a 5.2% dividend increase for Q1 2026, and in 2025, the company returned significant capital to shareholders, including $3.5 billion for share repurchases and $1.2 billion in dividends [4] Business Overview - Aflac Incorporated provides supplemental health and life insurance in the U.S. and Japan, offering financial protection to policyholders [5]

Core Viewpoint - Aflac is addressing Japan's demographic challenges through innovation in products and market strategies, focusing on growth while maintaining expense discipline and profitability [1][3]. Financial Performance - Aflac returned nearly $4.8 billion to shareholders in 2025, including $3.5 billion in share repurchases, marking a record year and extending its dividend increase streak to 43 consecutive years [2][4]. - The company is targeting an internal capital marker near 10%, currently at approximately 6% [4][17]. Market Dynamics - In the U.S., brokers account for about 80% of the market and generated over 60% of Aflac's U.S. sales in 2025, contributing to a 14% growth in overall group products [5][13]. - Aflac is experiencing sales momentum in Japan, particularly with products aimed at younger customers, and is expanding its distribution through banks and agencies [6][11]. Product Innovation - Key products driving growth include Tsumitasu, Miraito, and Anshin Palette, with Tsumitasu designed to adjust rates as interest rates change, providing a competitive edge [9][10][12]. - The company is leveraging AI to enhance agent efficiency and streamline enrollment processes, particularly in Japan [14]. Strategic Focus - Aflac remains committed to organic growth and does not pursue M&A unless it aligns with operational and strategic goals, emphasizing a focus on supplemental health products [18]. - The company sees significant underpenetrated opportunities in the U.S. market, particularly in dental and vision insurance, and plans to increase advertising to communicate product value [19].

Core Insights - Aflac Incorporated reported a decline in total revenues and net earnings for the fourth quarter and full year of 2025 compared to 2024, indicating challenges in financial performance [1][5][18]. Financial Performance - Total revenues for Q4 2025 were $4.9 billion, down from $5.4 billion in Q4 2024, representing a decrease of 9.9% [1][25]. - Net earnings for Q4 2025 were $1.4 billion, or $2.64 per diluted share, compared to $1.9 billion, or $3.42 per diluted share in Q4 2024, reflecting a decline of 27.5% [1][26]. - For the full year 2025, total revenues decreased by 9.3% to $17.2 billion from $18.9 billion in 2024 [5][25]. - Net earnings for the full year 2025 were $3.6 billion, or $6.82 per diluted share, down from $5.4 billion, or $9.63 per diluted share in 2024, marking a 33.0% decline [5][26]. Investment Gains - Q4 2025 net investment gains were $537 million, or $1.03 per diluted share, compared to $1.0 billion, or $1.86 per diluted share in Q4 2024 [2][32]. - The investment gains were influenced by net gains on derivatives and foreign currency activities, alongside losses from sales and redemptions [2]. Adjusted Earnings - Adjusted earnings for Q4 2025 were $818 million, down 5.4% from $865 million in Q4 2024 [3][32]. - Adjusted earnings per diluted share increased by 0.6% to $1.57 in Q4 2025 [3][32]. - For the full year 2025, adjusted earnings were $4.0 billion, or $7.49 per diluted share, compared to $4.1 billion, or $7.21 per diluted share in 2024, reflecting a slight decrease of 1.6% [5][34]. Shareholders' Equity - Shareholders' equity at the end of Q4 2025 was $29.5 billion, or $56.85 per share, up from $26.1 billion, or $47.45 per share at the end of Q4 2024 [4][37]. - The increase in shareholders' equity was attributed to changes in discount rate assumptions on insurance reserves [4]. Aflac Japan Performance - In yen terms, Aflac Japan's net earned premiums for Q4 2025 were ¥252.6 billion, a decrease of 1.9% year-over-year [7][8]. - Adjusted net investment income in yen decreased by 3.9% to ¥97.4 billion [7]. - For the full year, net earned premiums in yen were ¥1.0 trillion, down 3.9% from the previous year [8]. Aflac U.S. Performance - Aflac U.S. net earned premiums increased by 4.0% to $1.5 billion in Q4 2025, reflecting improved sales [12][13]. - Total adjusted revenues for Aflac U.S. were up 3.3% to $1.7 billion in Q4 2025 [12]. - For the full year, net earned premiums increased by 2.9% to $6.0 billion [13]. Capital Management - The board declared a first-quarter dividend of $0.61 per share, payable on March 2, 2026 [17]. - Aflac repurchased $800 million worth of shares in Q4 2025, with a total of $3.5 billion in share repurchases for the year [17][22].